Pancreatic Stone Protein (PSP) Biomarkers: A Game-Changer in Early Sepsis Detection at the Point of Care
Healthcare providers, emergency care givers and all point of care facilities must make it a priority to detect sepsis early in order to save lives. There is a growing body of evidence that supports the use of biomarker detection, in particular, Pancreatic Stone Protein (PSP).
Why PSP?
There are several reasons why PSP is increasingly becoming the test of choice for early detection of sepsis.
Firstly, PSP has been shown to be one of the earliest signs of sepsis, and it can be detected up to 3 days before any clinical symptoms appear – even in critically ill patients.i
In addition, PSP testing has been found to be more cost-effective than other options in the diagnosis of sepsis. This is important to facilitate uptake among hospitals and therefore increase access to reliable testing for patients in emergency medical situations. In fact, one studyii estimated significant cost savings of US$1688 (AUD$2560) per patient in the emergency department and US$3315 (AUD$5028) per patient in the ICU, compared to the current standard of care. In particular, the specificity and sensitivity of PSP were found to drive these cost-efficiencies.
Another studyiii found PSP to deliver better predictive ability for ICU mortality than other biomarkers of infection, such as CRP. The authors suggested that PSP is a prognostic biomarker in these situations and facilitates more precise management of sepsis in the ICU environment.
Clinical application
The success of PSP detection for early sepsis diagnosis has been indicated for clinical application in several environments. From emergency departments to the ICU, testing for PSP is quick and easy with the latest, specially designed technology.
The Abionic abioSCOPE® and IVD Capsule PSP from Getz Healthcare offer a fast and efficient solution. Intuitive to use, medical staff can complete bedside testing with a single drop of blood from a standard capillary blood collection. The system ensures the sample remains contamination-free and lab-quality results are returned in just 5 minutes.
Easy to use solution
Just open the IVD Capsule PSP, collect the blood sample, insert the abioPIPETTE® into the abioMIX® and dispense the blood sample. Once mixed, the pipette should be filled with the provided solution and then deposited into the capsule. The capsule is then inserted into the abioSCOPE®, patient data added and results displayed. You can see for yourself how simple it is to use in this VIDEO.
Care your patients deserve
Everything you do is to deliver the highest quality of patient care possible. No matter why a patient presents in the emergency room or ICU, giving them the best chance of a fast recovery means preventing sepsis. Early detection of the disease is therefore crucial.
i Pugin, J., Daix, T., Pagani, JL. et al. Serial measurement of pancreatic stone protein for the early detection of sepsis in intensive care unit patients: a prospective multicentric study. Crit Care 25, 151 (2021). https://doi.org/10.1186/s13054-021-03576-8
ii Schneider, J.E., Dick, K., Cooper, J.T. et al. Pancreatic stone protein point-of-care testing can reduce healthcare expenditure in sepsis. Health Econ Rev 12, 39 (2022). https://doi.org/10.1186/s13561-022-00381-z
iii Zuercher, P., Moser, A., Garcia de Guadiana-Romualdo, L. et al. Discriminative performance of pancreatic stone protein in predicting ICU mortality and infection severity in adult patients with infection: a systematic review and individual patient level meta-analysis. Infection 51, 1797–1807 (2023). https://doi.org/10.1007/s15010-023-02093-w